The ALK fusion gene was first identified in anaplastic large-cell lymphoma (ALCL), and has since been implicated in several types of cancer, including colorectal carcinoma (CRC), inflammatory myofibroblastic tumor (IMT); B-cell lymphoma (BCL); non-small-cell lung cancer (NSCLC); non-Hodgkin’s lymphoma (NHL); neuroblastoma, and other less common malignancies (Holla et al., 2017). This evidence concerns the gene ALK and non-small cell lung carcinoma.